menu search

KRTX / Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter. Read More
Posted: Nov 3 2023, 12:02
Author Name: Zacks Investment Research
Views: 052192

KRTX News  

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

By Zacks Investment Research
November 3, 2023

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter. more_horizontal

Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia

By Seeking Alpha
October 16, 2023

Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. The stock h more_horizontal

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress

By Business Wire
October 4, 2023

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative more_horizontal

Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug

By Zacks Investment Research
September 29, 2023

Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studi more_horizontal

Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT

By Seeking Alpha
August 24, 2023

Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT

Submission of New Drug Application of KarXT for the treatment of schizophrenia is expected in Q3, 2023. If FDA approval of KarXT is given for the trea more_horizontal

Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)

By Seeking Alpha
August 16, 2023

Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)

Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizop more_horizontal

Karuna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 5, 2023

Karuna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Call Transcript

Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Directo more_horizontal

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2

By Zacks Investment Research
August 4, 2023

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2

Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales. more_horizontal


Search within

Pages Search Results: